What’s Hot – JBY, XF1, TEG, PAT, MM8 & PNT
What’s Hot, Not & Doing Brought to you by TSN Contributor & Wealth Advisor Nick Kelso What’s Hot – JBY, XF1, TEG, PAT, MM8 & PNT What’s Not – WEB & STM What’s Hot JBY – James Bay Minerals Limited today closed up 75% to finish at 35c on $2.2m stock traded. The reason they […]
What’s Hot – IR1, NAG, MTM, CC9, MM8, AGH, ALA, PNT, WSR & AUN
What’s Hot, Not & Doing Brought to you by TSN Contributor & Wealth Advisor Nick Kelso What’s Hot – IR1, NAG, MTM, CC9, MM8, AGH, ALA, PNT, WSR & AUN What’s Not – NMT What’s Hot IR1 – Iris Metals Limited today closed up 103% to finish at 36.5c on $840k stock traded. The reason […]
Optiscan Imaging (ASX:OIL): MedTech bridging the gap between surgery & pathology
Shares in Optiscan Imaging (ASX:OIL) have surged more than 170 per cent over the last year as the commercial stage medical technology company advances its suite of digital pathology and precision surgery hardware and software solutions. Optiscan is focused on the development, manufacturing, and commercialisation of imaging technologies for medical, translational and pre-clinical applications. Ahead […]
PolyNovo (ASX:PNV): Growing global sales on the back of medical device innovation
Shares in PolyNovo (ASX:PNV) are up more than 100% over the last year on the back of the development and commercialisation of the Company’s innovative medical devices using its patented NovoSorb technology. PolyNovo medical devices are used for a number of medical applications and the Company has this year achieved record revenues of the back […]
What’s Hot – RIM, AUZ, PTR, PIZ, MKR, LV1, PNT, LYN, BRK & SRZ
What’s Hot, Not & Doing Brought to you by TSN Contributor & Wealth Advisor Nick Kelso What’s Hot – RIM, AUZ, PTR, PIZ, MKR, LV1, PNT, LYN, BRK & SRZ What’s Not – SBL What’s Hot RIM – Rimfire Pacific Mining Limited today closed up 38% to finish at 5.5c on $1.7m stock traded. There […]
Neuren Pharmaceuticals (ASX:NEU) continues PMS Phase 3 preparations following positive FDA meeting
Neuren Pharmaceuticals (ASX:NEU) has announced positive outcomes from an End of Phase 2 Meeting with the US Food and Drug Administration (FDA) to discuss proposals for the first ever pivotal clinical trial program in Phelan-McDermid syndrome (PMS) with the FDA. There are no medications approved for PMS, which has severe quality of life impacts on […]
Praemium Limited (ASX:PPS): Providing services to meet demands of high net wealth clients
Ahead of appearing at the Stocks On Track event, Praemium Limited (ASX:PPS) Chief Executive Officer, Anthony Wamsteker, speaks with The Stock Network’s Lel Smits and highlights: 🏆 Focus on earnings growth in FY24 ⚙️ FY25 outlook Watch the full interview ⚡ https://youtu.be/W8uMkbhzPtY
Praemium (ASX:PPS): Providing services to meet demands of high net wealth clients
Praemium (ASX:PPS) has created a platform of administration, investment and retirement-related services meeting the personalisation and customisation standards demanded by high-net-worth clients. Its offering includes full-suite reporting and administration services simplifying portfolios. Praemium’s services also give clients with holdings in more complex investment categories such as bonds, property, art and private equity, a workable way […]
PainChek (ASX:PCK): Has progressed with FDA De Novo submission
PainChek (ASX:PCK), developer of the world’s first smart phone-based pain assessment and monitoring application, has provided an update on its progress with FDA de Novo submission for the PainChek Adult App. – Majority of requirements for submission complete – Clinical Evaluation Report in final stages – PainChek expects to provide a further update this month […]
PainChek (ASX:PCK) completes majority of FDA de Novo submission requirements
PainChek (ASX:PCK), developer of the world’s first smart phone-based pain assessment and monitoring application, has progressed the US Food and Drug Administration De Novo (FDA De Novo) submission for the Company’s PainChek Adult App. Majority of requirements for submission complete – Clinical Evaluation Report in final stages PainChek expects to provide a further update this […]